BNP Paribas Financial Markets
NNNN

BNP Paribas Financial Markets’s Anbio Biotechnology NNNN Stock Holding History

BNP Paribas Financial Markets’s Portfolio NNNN Stock Details NNNN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$267K Buy
10,400
+9,400
+940% +$245K ﹤0.01% 3917
2025
Q4 		$30.1K Sell
1,000
-1,419
-59% -$39K ﹤0.01% 4907
2025
Q3 		$90.1K Buy
2,419
+1,158
+92% +$52K ﹤0.01% 4341
2025
Q2 		$39.9K Buy
+1,261
New +$12.1K ﹤0.01% 4342

Other funds holding NNNN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFS
Bare Financial Services Gap, Pennsylvania $436M AUM 20.22% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

BNP Paribas Financial Markets's NNNN Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Anbio Biotechnology (NNNN) stake by 940% in Q1 2026, buying an estimated $245K and bringing the position to 10,400 shares worth $267K. The position accounts for ﹤0.01% of the portfolio, ranked #3917.

BNP Paribas Financial Markets first reported a position in NNNN in Q2 2025 and has held it in 4 quarters since. 8 funds tracked by Wall St. Rank hold NNNN as of Q1 2026.

  • BNP Paribas Financial Markets held 10,400 shares of Anbio Biotechnology worth $267K as of Q1 2026.
  • BNP Paribas Financial Markets bought 9,400 Anbio Biotechnology shares in Q1 2026, an estimated $245K.
  • Anbio Biotechnology made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #3917 holding.
  • BNP Paribas Financial Markets first reported a position in Anbio Biotechnology in Q2 2025 and has held it in 4 quarters since.
  • 8 funds tracked by Wall St. Rank held Anbio Biotechnology as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.